Trupanion (TRUP) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
Achieved record year in 2025 with total revenue of $1.44 billion, up 12% year-over-year, and strong Q4 performance; subscription revenue rose 16% to $989.3 million.
Net income for 2025 was $19.4 million, reversing a net loss of $9.6 million in 2024, aided by a $7.8 million realized gain from a preferred stock exchange.
Nearly 1.1 million pets protected at year-end, with consistent expansion and high retention rates.
Focused on brand expansion, member retention, and new product development to drive future growth.
Achieved four consecutive quarters of higher retention and accelerating gross pet adds.
Financial highlights
Q4 2025 total revenue was $376.9 million, up 12% year-over-year; subscription revenue was $261.4 million, up 15%.
Free cash flow for Q4 was $25.3 million, up from negative $1.9 million in Q4 2024; full-year free cash flow was $75.4 million, nearly doubling year-over-year.
Net income for Q4 was $5.6 million ($0.13 per share), up from $1.7 million ($0.04 per share) last year.
Ended 2025 with $370.7 million in cash and short-term investments and $111.8 million in debt.
Subscription business margin reached 14.7% for the year, up from 12.6% in 2024.
Outlook and guidance
2026 total revenue expected between $1.55 billion and $1.582 billion; subscription revenue between $1.117 billion and $1.137 billion (14% growth at midpoint).
Adjusted operating income for 2026 projected at $173–$187 million (19% growth at midpoint).
Q1 2026 revenue guidance: $376–$382 million; subscription revenue $265–$268 million; AOI $38–$41 million (27% growth at midpoint).
Guidance assumes veterinary inflation in line with current trends and uses a 73% USD/CAD conversion rate.
Management highlighted four consecutive quarters of higher retention and accelerating gross pet adds, supporting confidence in the next strategic plan.
Latest events from Trupanion
- Strong growth, data-driven innovation, and new products position the company for market expansion.TRUP
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Low market penetration and strong recurring revenue signal major growth potential.TRUP
Investor presentation2 Mar 2026 - 2026 guidance highlights pricing-led growth, margin expansion, and broader customer acquisition.TRUP
BofA Securities Animal Health Summit26 Feb 2026 - Q2 2024 revenue up 16%, margins and cash flow improved, and pet retention remained strong.TRUP
Q2 20242 Feb 2026 - Margin expansion, strong retention, and capital surplus drive disciplined growth and innovation.TRUP
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Sustainable growth driven by vet channel, margin recovery, and international expansion.TRUP
Investor Day 202420 Jan 2026 - Q3 2024 saw 15% revenue growth, margin expansion, and improved free cash flow and guidance.TRUP
Q3 202417 Jan 2026 - Q1 2025 saw 12% revenue growth, higher margins, and improved retention with raised guidance.TRUP
Q1 202526 Dec 2025 - 2025 will see renewed marketing investment, high retention, and continued tech-driven growth.TRUP
Raymond James & Associates’ 46th Annual Institutional Investors Conference 202523 Dec 2025